<DOC>
	<DOC>NCT00403845</DOC>
	<brief_summary>The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen for testing in later studies.</brief_summary>
	<brief_title>Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Male and female Japanese aged 40 to 75 years old Moderate to severe chronic obstructive pulmonary disease (COPD) with smoking history of at least 20 pack years History of hospitalization for COPD exacerbation within past 6 months Use of longterm oxygen therapy History of asthma Respiratory tract infection within past 1 month Consistently very high or low blood sugar Clinically abnormal laboratory values or significant condition History of heart failure or heart attack within past 6 months History of long QT syndrome or long QT interval in electrocardiogram recorded at screening Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>QAB149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long acting β2-agonist</keyword>
</DOC>